Project Grant R56EY037651
- Federal Project Grant Award Summary The University of Connecticut Health Center received a $1.47 million Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 15, 2025, with completion targeted for August 31, 2028. This research initiative investigates corneal and Schwann cell mechanisms of injury caused by vesicant chemical agents, specifically nitrogen mustard. The project delivers...
- Federal Grant Award Summary The Schepens Eye Research Institute, Inc. received a $295,500 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), with an award date of September 15, 2025, and completion deadline of August 31, 2027. The research initiative focuses on developing a therapeutic countermeasure using alpha-melanocyte-stimulating hormone (α-MSH), a neuropeptide with cytoprotective and...
- Federal Project Grant Award Summary Wake Forest University Health Sciences received a $1.36 million Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective April 1, 2026, through March 31, 2029. The award funds research to identify single-cell determinants of corneal injury progression following sulfur mustard exposure. The research employs advanced molecular techniques—specifically...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $1.41 million project grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), with an award date of May 1, 2026, and completion date of April 30, 2029. The grant funds research to investigate the pathological mechanisms of sulfur mustard gas keratopathy (MGK), a chronic ocular injury resulting from chemical warfare...
- Federal Project Grant Award Summary The University of Texas Medical Branch at Galveston received a $2.88 million Project Grant award from the NIH Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) on September 15, 2025, with a completion date of August 31, 2028. The grant funds research investigating the role of Sirtuin 6 (SIRT6) in acrolein-induced ocular injury. Acrolein, a highly toxic volatile aldehyde with widespread industrial use and historical deployment as...
- Federal Project Grant Award Summary Michigan State University's Henry Ford Health+Michigan State University Health Sciences partnership received a $1,403,056 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) effective April 23, 2026, through April 22, 2029. This award funds research to identify mechanisms of lung toxicity resulting from skin exposure to vesicating chemical agents, including sulfur...
- Federal Project Grant Award Summary The University of Tennessee received a $413,069 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) beginning April 1, 2026, and concluding February 28, 2031. This award supports fundamental biomedical research investigating the spatial regulation of plasma membrane signaling in immune cells. The research employs super-resolution fluorescence imaging and...
- Federal Project Grant Award Summary The University of Virginia received a $1.46M Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective April 14, 2026, through April 13, 2029. This award funds research to develop therapeutic interventions targeting vesicant-induced lung injury caused by chemical agents such as sulfur mustard and nitrogen mustard. The research focuses on leveraging MG53...
- The University of Tennessee received a $406,112 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for research spanning March 5, 2026 through February 28, 2031. The grant supports pioneering mass spectrometry (MS)-based footprinting research aimed at revealing the higher-order structure and functional properties of human integral membrane proteins (IMPs) in their native cellular and tissue...
- The University of Tennessee received a $436,547 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2027. The award funds development of a computational model to determine fluid bilayer membrane structure from cryogenic electron microscopy (cryo-EM) images of biomembranes. This research aims to establish proof-of-principle for using cryo-EM to...
The University of Tennessee Health Science Center (UTHSC) received a $466,103 Project Grant awarded May 1, 2026, through the Trans-NIH Research Support program (CFDA 93.310), administered by the National Institutes of Health (NIH) Office of the Director. The one-year award, with completion scheduled for April 30, 2027, funds research characterizing sphingolipid signaling pathways in ocular injuries caused by vesicating chemical-threat agents such as sulfur mustard and nitrogen mustard. The project delivers scientific research and analysis services focused on understanding the complex pathophysiological mechanisms underlying acute and chronic eye damage from these agents. The funded research develops and characterizes nitrogen mustard-induced ocular surface injury (NMOSI) models in mice to elucidate the role of bioactive sphingolipid pathways in vesicant-related corneal, conjunctival, and eyelid damage. The project aims to provide critical foundational knowledge to support the development of medical countermeasures (MCMs) for treating vesicant-induced ocular injuries, addressing a significant gap in available therapeutic options. Research activities performed in Memphis, Tennessee will generate data and insights on sphingomyelinase activation, ceramide signaling, and associated inflammatory responses that characterize the biphasic pathology of vesicant eye injury, ultimately informing the design of potential therapeutic interventions for chemical exposure casualties.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $466.1k | 5/12/26 |